Literature DB >> 10817445

Effects of the anti-migraine drug sumatriptan on muscle energy metabolism: relationship to side-effects.

M D Boska1, K M Welch, L Schultz, J Nelson.   

Abstract

Sumatriptan succinate (Imitrex) is a 5-HT (5-hydroxytryptamine) agonist used for relief of migraine symptoms. Some individuals experience short-lived side-effects, including heaviness of the limbs, chest heaviness and muscle aches and pains. The effects of this drug on skeletal muscle energy metabolism were studied during short submaximal isometric exercises. We studied ATP flux from anaerobic glycolysis (An Gly), the creatine kinase reaction (CK) and oxidative phosphorylation (Ox Phos) using 31P nuclear magnetic resonance spectroscopy (31P MRS) kinetic data collected during exercise. It was found that side-effects induced acutely by injection of 6 mg sumatriptan succinate s.c. were associated with reduced oxygen storage in peripheral skeletal muscle 5-20 min after injection as demonstrated by a transient reduction in mitochondrial function at end-exercise. These results suggest that mild vasoconstriction in peripheral skeletal muscle is associated with the action of sumatriptan and is likely to be the source of the side-effects experienced by some users. Migraine with aura patients were more susceptible to this effect than migraine without aura patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10817445     DOI: 10.1046/j.1468-2982.2000.00009.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  2 in total

Review 1.  Almotriptan: a review of its use in migraine.

Authors:  Susan J Keam; Karen L Goa; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Development of Optimized Sumatriptan-Prochlorperazine Combined Orodispersible Films Without Disintegrant: in vitro, ex vivo and in vivo Characterization.

Authors:  Sana Javed; Amjad Hussain; Pervaiz Akhtar Shah; Syed Atif Raza; Ubaid Ullah Anwer; Rahat Shamim; Fatima Rasool; Muhammad Ahsan Hafiz; Nadeem Irfan Bukhari
Journal:  AAPS PharmSciTech       Date:  2022-06-02       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.